ERNA Quote, Financials, Valuation and Earnings

Ocular Therapeutix, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of -487.96%. Ernexa Therapeutics, Inc.'s return on equity of -- beat Ocular Therapeutix, Inc.'s return on equity of -73.88%.

Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 315578.55%. On the other hand Ocular Therapeutix, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 187.1%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Ocular Therapeutix, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Ocular Therapeutix, Inc..

Ernexa Therapeutics, Inc. has a beta of 6.577, which suggesting that the stock is 557.698% more volatile than S&P 500. In comparison Ocular Therapeutix, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.316%.

Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Ocular Therapeutix, Inc. pays out -- of its earnings as a dividend.

Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Ocular Therapeutix, Inc. quarterly revenues of $13.3M. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Ocular Therapeutix, Inc.'s net income of -$64.7M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Ocular Therapeutix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 8,421.28x versus 32.22x for Ocular Therapeutix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quince Therapeutics, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of --. Ernexa Therapeutics, Inc.'s return on equity of -- beat Quince Therapeutics, Inc.'s return on equity of -267.62%.

Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 315578.55%. On the other hand Quince Therapeutics, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -100%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Quince Therapeutics, Inc..

Ernexa Therapeutics, Inc. has a beta of 6.577, which suggesting that the stock is 557.698% more volatile than S&P 500. In comparison Quince Therapeutics, Inc. has a beta of 1.282, suggesting its more volatile than the S&P 500 by 28.179%.

Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quince Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Quince Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Quince Therapeutics, Inc. quarterly revenues of --. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Quince Therapeutics, Inc.'s net income of -$13.4M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Quince Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 8,421.28x versus -- for Quince Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of -304.24%. Ernexa Therapeutics, Inc.'s return on equity of -- beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 315578.55%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Ernexa Therapeutics, Inc. has a beta of 6.577, which suggesting that the stock is 557.698% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 8,421.28x versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of 29.52%. Ernexa Therapeutics, Inc.'s return on equity of -- beat Tango Therapeutics, Inc.'s return on equity of -56.44%.

Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 315578.55%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $15.67 which suggests that it could grow by 40.63%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Tango Therapeutics, Inc..

Ernexa Therapeutics, Inc. has a beta of 6.577, which suggesting that the stock is 557.698% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.761, suggesting its more volatile than the S&P 500 by 76.144%.

Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. Ernexa Therapeutics, Inc.'s net income of -$1.2M is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 8,421.28x versus 18.45x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.